// App-Quantinova.ai

4904 : The BET inhibitor INCB054329 enhances the activity of checkpoint modulation in syngeneic tumor models

Researchers

Presenter

  • Holly K. Koblish

Principal Investigators

  • Leslie Hall

  • Liang-Chuan Wang

  • Yue Zhang

  • Maryanne Covington

  • Timothy Burn

  • Mark Rupar

  • Christine Gardiner

  • Thomas Condamine

  • Kerri Lasky

  • Matthew C. Stubbs

  • Eddy Yue

  • Richard Sparks

  • Thomas Maduskuie

  • Andrew P. Combs

  • Gregory Hollis

  • Reid Huber

  • Phillip CC Liu

  • Peggy Scherle

Medical Centers

  • Incyte Corporation, Wilmington, DE

Locations

  • United States

Companies

  • Incyte Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Indoleamine 2,3-dioxygenase 1

Drug/Treatment

  • epacadostat

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved